Sugi Predict

Sugi Predict / Compounds / SCHEMBL24364213

SCHEMBL24364213

SCHEMBL24364213

CC(C)(C)OC(=O)N1CC2CCC(C2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.41
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ HSD11B1 P28845 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ AR P10275 1/20 0.33
▸ ELANE P08246 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31444300 0.89 KDM4E (0.43) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL3747007 0.73 NR1H2 (0.43) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL30326282 0.73 NR1H2 (0.43) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL31509818 0.72 LIPE (0.40) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL24365670 0.72 NR1H2 (0.39) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL29551497 0.72 CHRM2 (0.49) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL1192344 0.72 CHRM2 (0.49) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL23583804 0.72 CHRM2 (0.49) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL3739276 0.72 LIPE (0.40) KDM4ECHRM2CHRM1CHRM3MAPT
SCHEMBL1192343 0.72 CHRM2 (0.49) KDM4ECHRM2CHRM1CHRM3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 KDM4E 3895/4885CHRM2 13/4885CHRM1 7/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 KDM4E 3895/4885CHRM2 13/4885CHRM1 7/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 KDM4E 4822/4885CHRM2 158/4885CHRM1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.